Terms: = Germ cell tumor AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
538 results:
1. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
Jara MA
Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
[TBL] [Abstract] [Full Text] [Related]
2. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
3. The role of prophylactic parathyroidectomy during thyroidectomy for MTC in patients with men2a syndrome.
Kavazis C; Romanidis K; Pitiakoudis M; Kesisoglou I; Laskou S; Sapalidis K
Folia Med (Plovdiv); 2023 Oct; 65(5):720-727. PubMed ID: 38351753
[TBL] [Abstract] [Full Text] [Related]
4. ret kinase inhibitors for the treatment of ret-altered thyroid cancers: Current knowledge and future directions.
Hamidi S; Hu MI
Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
[TBL] [Abstract] [Full Text] [Related]
5. Thyroid Cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract] [Full Text] [Related]
6. Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci.
Mao YV; Hughes EG; Steinmetz D; Troob S; Kim J; Tseng CH; Fishbein GA; Sajed DP; Livhits MJ; Yeh MW; Lee D; Angell TE; Wu JX
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):209-214. PubMed ID: 38270925
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and safety of pralsetinib in Chinese advanced ret-mutant medullary thyroid cancer patients.
Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
[TBL] [Abstract] [Full Text] [Related]
8. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
Brandenburg T; Machlah YM; Führer D
Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.
Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
[TBL] [Abstract] [Full Text] [Related]
10. Patterns of treatment Failure After Selective Rearranged During Transfection (ret) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
11. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (ret)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
12. The Evolving treatment Landscape of Medullary Thyroid Cancer.
Laganà M; Cremaschi V; Alberti A; Vodopivec Kuri DM; Cosentini D; Berruti A
Curr Treat Options Oncol; 2023 Dec; 24(12):1815-1832. PubMed ID: 37979019
[TBL] [Abstract] [Full Text] [Related]
13. Longitudinal Natural History Study of Children and Adults with Rare Solid tumors: Initial Results for First 200 Participants.
Ahmed S; Wedekind MF; Del Rivero J; Raygada M; Lockridge R; Glod JW; Flowers C; Thomas BJ; Bernstein DB; Kapustina OB; Jain A; Miettinen M; Raffeld M; Xi L; Tyagi M; Kim J; Aldape K; Malayeri AA; Kaplan RN; Allen T; Vivelo CA; Sandler AB; Widemann BC; Reilly KM;
Cancer Res Commun; 2023 Dec; 3(12):2468-2482. PubMed ID: 37966258
[TBL] [Abstract] [Full Text] [Related]
14. [Systemic therapies for advanced thyroid cancer - an update].
Brandenburg T; Machlah YM; Führer-Sakel D
Dtsch Med Wochenschr; 2023 Nov; 148(22):1412-1418. PubMed ID: 37918424
[TBL] [Abstract] [Full Text] [Related]
15. Pheochromocytoma and paraganglioma in children and adolescents.
Stachowicz-Stencel T; Pasikowska N; Synakiewicz A
Acta Biochim Pol; 2023 Sep; 70(3):487-493. PubMed ID: 37717273
[TBL] [Abstract] [Full Text] [Related]
16. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
17. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
[TBL] [Abstract] [Full Text] [Related]
18. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
;
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2037-2074. PubMed ID: 37455124
[TBL] [Abstract] [Full Text] [Related]
19. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
Fazio N; La Salvia A
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
[TBL] [Abstract] [Full Text] [Related]
20. Diagnosis and treatment of bilateral adrenal pheochromocytoma with ret gene mutation combined with medullary sponge kidney: A case report.
Shen P; Yin N; Sun L; Liu Y; Cao X
Medicine (Baltimore); 2023 Jun; 102(23):e34022. PubMed ID: 37335636
[TBL] [Abstract] [Full Text] [Related]
[Next]
